ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31

Adagene Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026

$2.29+0.23 (+11.17%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Adagene Inc. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	7.67	0.10	18	9.29	10	0.70	0.48	1.51
Research & Development	22	29	37	81	68	34	16	16
General & Administrative	7.08	7.27	8.67	12	14	10	3.44	2.77
Operating Income	-21	-36	-24	-84	-72	-43	-19	-17
Interest Expense	0.46	0.85	1.11	0.69	0.36	0.20	0.14	0.09
Interest & Investment Income	2.30	3.80	4.28	0.38	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	–	-0.02	0.00	0.00	0.00
Pretax Income	-18	-33	-16	-13	-17	-42	-16	-15
Income Tax Expense	-0.30	-0.02	1.69	0.46	1.70	–	–	–
Net Income incl. Noncontrolling Interests	-18	-33	-19	-80	-73	-42	-16	-15
Net Income	-18	-33	-19	-80	-73	-42	-16	-15
Net Income to Common	-18	-33	-19	-80	-73	-43	-17	-14
EPS (Basic)(per share)	-0.30	-0.59	-0.35	-1.48	-1.46	-2.67	-1.10	-0.94
EPS (Diluted)(per share)	-0.30	-0.59	-0.35	-0.31	-1.46	-2.67	-1.10	-0.94
Shares Outstanding (Basic, Weighted)(shares)	59	56	55	54	50	16	15	15
Shares Outstanding (Diluted, Weighted)(shares)	59	56	55	55	50	16	15	15
EBITDA	-21	-35	-23	-83	-71	-42	-18	-16

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -279.5%
Net margin: -229.6%
Return on equity, FY2025: -41.0%

Financial strength

Current ratio: 5.02
Debt to equity: 0.06
Debt to assets: 4.3%
Cash to current liabilities: 485.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –